Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1094546


Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec


Description: Chronic myelogenous leukemia (CML) is a rare blood cancer; nonetheless, CML treatments garner substantial revenues. Despite recent advances in the treatment of this disease (most notably, targeted therapeutics such as Novartis’s Gleevec/Glivec [imatinib]), significant unmet needs remain because certain segments of the CML patient population are intolerant of or become resistant to existing therapies. Emerging therapies that focus on the unmet needs of current therapeutics have a good chance of replicating Gleevec’s success.

Questions Answered in This Report

Properly diagnosing CML is an integral part of choosing an effective treatment.
- How is CML diagnosed?
- What role does genetic testing play in developing and deploying drugs for CML?
- What are the symptoms of CML?

Treatment options for CML are more targeted today than in recent history.
- How was CML previously treated?
- Why have targeted therapies proved to be better CML treatment options?

Despite treatment advances, opportunities remain for emerging CML agents.
- What are these opportunities?
- Are the opportunities potentially lucrative enough to motivate drug developers?

Scope

- Disease overview: disease causes and indicators, physical and genetic symptoms, diagnosis, classification, epidemiology, and disease progression.

- Current CML therapies: chemotherapy, interferon-alpha, targeted therapies, stem cell therapy.

- Emerging CML therapies: targeted therapies, therapies focused on particular disease mutations.

- Market outlook: 2008 CML market sales, opportunities for current and emerging CML therapies.


Contents: Executive Summary
- Strategic Considerations
- Stakeholder Implications

Introduction

Disease Overview
- Etiology and Pathophysiology
- - BCR-ABL-Positive Patients
- - BCR-ABL-Negative Patients
- Diagnosis and Classification
- Patient Population, Symptoms, and Disease Progression

Current Therapies
- Drug Therapies
- - Novartis’s Gleevec
- - Novartis’s Tasigna
- - Bristol-Myers Squibb’s Sprycel
- - Interferon-Alpha
- - Generic Chemotherapeutic Agents
- Progenitor Stem Cell Transplantation
- - Myeloablative Regimens
- - Allogenic Progenitor Stem Cell Transplantation
- - Autologous Progenitor Stem Cell Transplantation

Emerging Therapies
- Wyeth’s Bosutinib (SKI-606)
- Novartis’s Panobinostat (LBH-589)
- ChemGenex Pharmaceuticals’ Omacetaxine Mepesuccinate

2008 Statistics and Market Outlook

Tables

1. Laboratory Features Characteristic of Chronic Myelogenous Leukemia
2. Poor Prognostic Factors for Chronic-Phase Chronic Myelogenous Leukemia
3. Commonly Used Current Therapies in the Treatment of Chronic MyelogenousLeukemia
4. Emerging Therapies for Chronic Myelogenous Leukemia
5. 2008 Worldwide Chronic Myelogenous Leukemia Market

Figures

1. The Philadelphia-Chromosome
2. Prevalent, Diagnosed Cases of Chronic Myelogenous Leukemia in the Major Pharmaceutical Markets, 2008 and 2013


Companies Mentioned - Bristol-Myers Squibb - ChemGenex Pharmaceuticals - CytRx - Deciphera Pharmaceuticals - Exelixis - Genzyme Genetics - Innate Pharma - Janssen Pharmaceutica - Kiadis - Novartis - Piramal Life Sciences - Roche - Schering-Plough - Wyeth


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/1094546

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 13/02/2012 08:47:18
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec
Web Address:
http://www.researchandmarkets.com/reports/1094546
Office Code:
OC8IHINLSNNSS

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €1,301.00
Electronic (PDF) - Enterprisewide €3,471.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 13/02/2012 08:47:18

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)